Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106828 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
A Phase 3 study of Thyroid Eye Disease, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 127
- Enrollment target
- 20
- Study locations
NCT06106828 is a Phase 3 study of Thyroid Eye Disease that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 127 participants, above the 98-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06106828, a Phase 3 study of Thyroid Eye Disease, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 127 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Satralizumab
Study Locations (20)
Other
- Peking Union Medical College Hospital - Beijing
- Peking University Third Hospital - Beijing
- Beijing Hospital of Ministry of Health - Beijing
- Beijing Tongren Hospital, Capital Medical University - Beijing
- Xi'an Fourth Hospital - Xi'an
- CHU Nantes - Hotel Dieu - Nantes
- CHNO Hopital des Quinze Vingts - Paris
- Fondation Rothschild - Paris
- Hadassah MC - Jerusalem
- Rabin MC - Petah Tikva
- Sheba medical center - Ramat Gan
California
- Plastics-Orbit-Neuro - San Diego
Connecticut
- Connecticut Eye Consultants, P.C. - Danbury
Illinois
- University of Illinois Eye and Ear Infirmary - Chicago
Pennsylvania
- Scheie Eye Institute - Philadelphia
Tennessee
- Vanderbilt Eye Institute - Nashville
Texas
- Retina Consultants of Texas - San Antonio
Alberta
- University of Alberta - Edmonton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2026-06-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06106828
The ClinicalTrials.gov registry entry for NCT06106828 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 98-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (30% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06106828 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06106828 about?
NCT06106828 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease". The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
What is the current status of trial NCT06106828?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 127 participants. The study started on 2023-11-15. Estimated completion is 2026-06-25.
What conditions does trial NCT06106828 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT06106828?
The interventions under investigation include: Placebo (DRUG), Satralizumab (DRUG).
Who is sponsoring clinical trial NCT06106828?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106828 being conducted?
This trial has 20 study locations across California, Connecticut, Illinois, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.